Research advances in epidemiological situation and diagnosis and treatment of metabolism-associated fatty liver disease
10.11855/j.issn.0577-7402.0545.2023.0807
- VernacularTitle:代谢相关脂肪性肝病的流行病学现状及诊治研究进展
- Author:
Ying-Jie ZHUANG
1
;
Wen-Hui LIU
;
Zheng-Yi LIU
;
Li-Li GAO
Author Information
1. 解放军总医院第二医学中心消化内科/国家老年疾病临床医学研究中心,北京 100853
- Keywords:
non-alcoholic fatty liver disease;
epidemiology;
risk factors;
diagnosis;
therapeutics
- From:
Medical Journal of Chinese People's Liberation Army
2023;48(12):1457-1466
- CountryChina
- Language:Chinese
-
Abstract:
Metabolism-associated fatty liver disease(MAFLD),formerly known as non-alcoholic fatty liver disease(NAFLD),is one of the most popular chronic liver diseases in the world,and has become one of the main causes of liver cirrhosis,end-stage liver disease,and primary liver cancer.In recent years,the prevalence of MAFLD has gradually increased in China,the Asia Pacific region,and even globally,increasing the medical and socio-economic burden.The exploration of the epidemiology and risk factors of this disease at home and abroad has also gradually increased.Meanwhile,due to the scarcity of MAFLD treatment drugs,their drug treatment has become a hot issue that needs to be urgently addressed in clinical practice.In recent years,there has been an increase in the number of drugs entering the clinical trial stage.Based on this,the current epidemiological status,risk factors,diagnostic criteria,and treatment research progress of MAFLD have been reviewed in order to provide new ideas and directions for the clinical diagnosis,treatment,and scientific research of MAFLD.
